Olaris, a leader in metabolomics and precision medicine, announced a strategic investment from Bruker Corporation (Nasdaq: BRKR), a global leader in scientific instrumentation and diagnostics solutions. The investment will support the continued development and commercialization of Olaris' proprietary metabolomics platform, which leverages machine learning and metabolite biomarker discovery to revolutionize how diseases are diagnosed, treated, and monitored.